药物基因组学指导下的抑郁症患者抗抑郁药处方的疗效与安全性：一项伞状综述与更新的荟萃分析
Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis.
作者信息
Tesfamicael Kiflu G, Zhao Lijun, Fernández-Rodríguez Rubén, Adelson David L, Musker Michael, Polasek Thomas M, Lewis Martin David
机构信息
School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.
Lifelong Health, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
出版信息
Front Psychiatry. 2024 Jul 11;15:1276410. doi: 10.3389/fpsyt.2024.1276410. eCollection 2024.
AIM
To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.
METHODS
A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data.
RESULTS
Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU).
CONCLUSION
PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.
目的
通过一项汇总分析和更新的荟萃分析，确定药物基因组学（PGx）指导下的抗抑郁药处方对抑郁症患者的疗效和安全性。
方法
对PsycINFO、PubMed、Embase和Cochrane数据库进行了全面的系统检索。随机对照试验（RCT）的合并效应量对于连续性数据表示为平均差，对于非连续性数据表示为风险比。
结果
与接受常规治疗（TAU）的患者相比，接受PGx指导用药的患者实现缓解的可能性高41%至78%，对抗抑郁药有反应的可能性高20%至49%。
结论
PGx指导下的抗抑郁药处方改善了抑郁症的治疗。然而，不同研究和不同PGx检测组之间，获益的显著性和程度差异很大。
系统评价注册
Zotero 插件